Vaccination News

CDC vaccine advisors said Wednesday that older adults in the United States should talk to their physicians about getting vaccinated against respiratory syncytial virus.

FDA advisors recommend that future COVID-19 vaccines be monovalent, targeting XBB sublineages of the omicron variant, after data showed that bivalent vaccines are less effective against currently circulating variants.

An FDA advisory committee voted Thursday to recommend changing the composition of the country’s COVID-19 vaccines to be monovalent XBB-lineage vaccines, removing the wild strain of SARS-CoV-2 from the shots.

Prompted by a large spike in cases last year, the CDC has reminded health care providers to ensure that all patients with HIV are fully vaccinated against meningococcal disease.

The FDA recently approved a new indication for Prevymis as a prophylaxis to prevent cytomegalovirus disease in high-risk adult kidney transplant patients receiving organs from CMV-seropositive donors.

The FDA recently approved two separate vaccines to prevent respiratory syncytial virus in older adults. Soon, additional RSV prevention tools may be available for pediatric patients, too.

A review of nearly 250,000 doses of messenger RNA COVID-19 vaccine administered to young children identified no serious side effects from the shots, according to results published in Pediatrics.

The FDA has recently approved Pfizer’s respiratory syncytial virus vaccine, branded as Abrysvo, for adults aged 60 years or older.

Among more than 72,000 blood donors in the United States aged 16 years or older, 96% had antibodies against the virus that causes COVID-19 by late last year, according to a new analysis.

The FDA this week approved Pfizer’s respiratory syncytial virus vaccine for adults aged 60 years or older — the second RSV vaccine approved for this population in the last month.